Výsledky vyhledávání - "Nancy, Harold"

A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer

Autor: Nancy Harold, Ravi A. Madan, David G. McLeod, Yusuke Tomita, William L. Dahut, Yunkai Yu, Min-Jung Lee, Sunmin Lee, Liang Cao, Cody J. Peer, William D. Figg, David E. Adelberg, Fatima Karzai, Howard L. Parnes, James L. Gulley, Andrea B. Apolo, Jane B. Trepel

Publikováno v: BJU International. 116:546-555

Objective TRC105 is a chimeric immunoglobulin G1 monoclonal antibody that binds endoglin (CD105). This phase I open-label study evaluated the safety, pharmacokinetics and pharmacodynamics of TRC105 in patients with metastatic castration-resistant pro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b8409c7ec77073b42bb4cde72dc1a7f7
https://doi.org/10.1111/bju.12986

Zobrazit plný text záznamu

Plný text ve formátu HTML

Molecular and Clinical Responses in a Pilot Study of Gefitinib With Paclitaxel and Radiation in Locally Advanced Head-and-Neck Cancer

Autor: Carter Van Waes, Liesl Nottingham, Anurag K. Singh, David Gius, A. Dimetrios Colevas, Janet Dancey, John C. Morris, Deborah Citrin, Christine Muir, Zhong Chen, Nancy Harold, Clint T. Allen, Susan F. Rudy

Publikováno v: International Journal of Radiation Oncology*Biology*Physics. 77:447-454

Purpose Epidermal growth factor receptor (EGFR) overexpression in head-and-neck squamous cell carcinoma (HNSCC) stimulates tumor cell proliferation, inhibits apoptosis, and increases chemotherapy and radiation resistance. We examined the toxicity, sa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a66ef486c2db50c892ba752a19114a3
https://doi.org/10.1016/j.ijrobp.2009.05.037

Zobrazit plný text záznamu

A Phase I Pharmacologic and Pharmacogenetic Trial of Sequential 24-Hour Infusion of Irinotecan Followed by Leucovorin and a 48-Hour Infusion of Fluorouracil in Adult Patients with Solid Tumors

Autor: Dat Nguyen, Barbara Schuler, Nancy Harold, Geraldine Morrison, Xaiodu Guo, Maurice A. Wright, Mary G. Quinn, Jorge P. Leguizamo, Janet Pang, Eva Szabo, Gregory D. Leonard, M. Wasif Saif, Suzanne Fioravanti, Brian P. Monahan, Jon L. Hopkins, Pengxin Lin, Jean L. Grem

Publikováno v: Clinical Cancer Research. 11:4144-4150

Purpose: In preclinical studies, sequential exposure to irinotecan (CPT-11) then fluorouracil (5-FU) is superior to concurrent exposure or the reverse sequence; a 24-hour infusion of CPT-11 may be better tolerated than shorter infusions. Experimental

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::315c80d9fa45b860a95addad65a8f657
https://doi.org/10.1158/1078-0432.ccr-04-2439

Zobrazit plný text záznamu

A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin

Autor: Chris H. Takimoto, Dat Nguyen, Alice P. Chen, J. Michael Hamilton, Brian P. Monahan, Janet Pang, Mary G. Quinn, Yan Xu, Jean L. Grem, Anthony Rowedder, Bruce Keith, Nancy Harold, Geraldine Morrison

Publikováno v: Cancer Chemotherapy and Pharmacology. 52:487-496

Since preclinical studies have shown more than additive cytotoxicity and DNA damage with the combination of gemcitabine and 5-fluoro-2'-deoxyuridine (FUDR), we studied this combination in a phase I trial.Gemcitabine alone was given in cycle 1 as a 24

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::332cce0c9225697893274395cf2a66ee
https://doi.org/10.1007/s00280-003-0698-5

Zobrazit plný text záznamu

A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer

Autor: Fatima H, Karzai, Andrea B, Apolo, Liang, Cao, Ravi A, Madan, David E, Adelberg, Howard, Parnes, David G, McLeod, Nancy, Harold, Cody, Peer, Yunkai, Yu, Yusuke, Tomita, Min-Jung, Lee, Sunmin, Lee, Jane B, Trepel, James L, Gulley, William D, Figg, William L, Dahut

Publikováno v: BJU international. 116(4)

TRC105 is a chimeric immunoglobulin G1 monoclonal antibody that binds endoglin (CD105). This phase I open-label study evaluated the safety, pharmacokinetics and pharmacodynamics of TRC105 in patients with metastatic castration-resistant prostate canc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c3915910472ae5a7b1e8ac02c28bbf70
https://pubmed.ncbi.nlm.nih.gov/26350576

Zobrazit plný text záznamu

Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion

Autor: Frank M. Balis, W. Corse, Chris H. Takimoto, David J. Liewehr, Mary Flanagan Quinn, Jean L. Grem, Robert F. Murphy, J M Hamilton, Carmen J. Allegra, Brian P. Monahan, Nancy Harold, Alice P. Chen, Janet Pang, Seth M. Steinberg, R. Lush, Abdel Salam Attia Ismail

Publikováno v: Cancer Chemotherapy and Pharmacology. 47:117-125

Purpose: Clinical toxicity associated with 5-fluorouracil (5-FU) is related to the area under the plasma concentration-time curve (AUC). Recently, short-term infusions of 5-FU given over 30 or 60 min have been substituted for conventional "bolus" 5-F

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f95c78225c9ae02d426e76afd3b2de8e
https://doi.org/10.1007/s002800000189

Zobrazit plný text záznamu

Clinical and immunologic impact of short course enzalutamide without androgen deprivation therapy for biochemically recurrent prostate cancer

Publikováno v: Journal of Clinical Oncology. 34:214-214

214 Background: Enzalutamide (enz) is FDA approved for advanced prostate cancer, but studies are evaluating enz in earlier stages of disease. We have conducted a clinical trial (NCT01875250) of enz ± a therapeutic vaccine in biochemically recurrent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b89c2aa9715cdb986da989556a358159
https://doi.org/10.1200/jco.2016.34.2_suppl.214

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání